INNATE PHARMA TO
HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON JUNE 23,
2017
Marseille, France, May 23, 2017, 7:00 AM
CEST
Innate Pharma (the "Company" -
Euronext Paris: FR0010331421 - IPH) will hold its Annual General
Meeting of Shareholders ("AGM") on June 23, 2017, at 10:00 am in
its headquarters, 117 avenue de Luminy, F-13009 Marseille.
The Notice of Meeting of this
Shareholders' Meeting was published on May 19, 2017, in the French
official legal bulletin ("BALO"). It includes the agenda, the
proposed resolutions as well as instructions to participate and
vote in this Meeting. It is also available on the Company's
website.
All documentation regarding this
AGM will be made available to shareholders in accordance with
existing regulations and will be available on the Company's website
as of today.
Among the resolutions, the
following will be proposed during the AGM:
- Renewals, as members of the
Supervisory board, for a period of two years, of Hervé Brailly,
Irina Staatz Granzer, Gilles Brisson, Véronique Chabernaud, Patrick
Langlois and Novo Nordisk A/S, represented by Karsten Munk
Knudsen;
- Appointment, as members of the
Supervisory board and for a period of two years, of Bpifrance
Participations, represented by Maïlys Ferrère, Head of the Large
Venture Investment Activity at Bpifance, and Professor Jean-Charles
Soria, Head of Drug Development department at Gustave Roussy cancer
center;
- Appointment, for a one year
period, of Olivier Martinez as observer of the Supervisory
board.
Professor Jean-Charles Soria will
replace Professor Michael Caligiuri, who has been named American
Association for Cancer Research (AACR) President and resigned from
the Supervisory board.
Hervé Brailly,
Chairman of the Supervisory board, commented: "On behalf of all Supervisory board members, I would
like to express our deepest gratitude to Professor Caligiuri, who
has just been named President of AACR, one of the most prestigious
worldwide cancer associations, for his commitment to the Board
during the four years of his mandate. His medical expertise and
experience have been valuable assets to the Board.
We propose the
appointment of Professor Jean-Charles Soria to succeed him.
Professor Jean-Charles Soria is an oncologist, Head of Drug
Development department at Gustave Roussy cancer center, and a
renowned world leader in the field of immuno-oncology.
We are also
pleased to propose the appointment of Bpifrance Participations,
represented by Maïlys Ferrère. Bpifrance Participations holds
Innate Pharma's shares since 2009 and has supported the Company
ever since. This appointment of Bpifrance Participations as member
of the Supervisory board shows once again their commitment to
Innate Pharma.
These proposals
guarantee the wealth, diversity and complementarity of profiles
which composed the Board and we will pursue our work thanks to the
expertise of each of its members."
Maïlys
Ferrère is Director of the Large Venture Investment Pole within
the Innovation Division of Bpifrance. Large Venture's mission is to
provide long term capital to innovative French companies in areas
with very strong growth with the goal of creating world leaders.
The portfolio currently includes thirty companies in life sciences,
digital and environmental technologies. Prior to this position,
Maïlys Ferrère was an Investment Director at the Strategic
Investment Fund between 2009 and 2012. She previously had a career
in banking, specialized in equity capital markets in various
financial institutions. Maïlys Ferrère is a member of the Boards of
Directors or Supervisory boards of the following companies: DBV,
Valneva SE, Pixium, Gensight and Euronext Paris.
Professor Jean-Charles Soria is a medical oncologist and a
Professor of Medicine and Medical Oncology at South-Paris
University. He is a full-time cancer specialist at Institut Gustave
Roussy. Professor Soria trained as a medical oncologist and
obtained the Silver medal from Paris Medical School in 1997. He
gained a postgraduate degree and a PhD degree in molecular biology
(fundamental basis of oncogenesis) in 2001, and completed his
training with a two-year post-doctoral fellowship at MD Anderson
Cancer Center, Houston, USA, where he has held an Adjunct
Professorship since 2012. Professor Soria is also a member of the
thoracic pathology committee at Gustave Roussy Cancer Center. He is
a recognized expert on targeted therapies, immunotherapy and lung
cancer. His main research interests are: early clinical
development, pharmacodynamic biomarkers, lung cancer, immunotherapy
and personalized medicine. He is also involved in translational
research aspects related to precision medicine and tumor
progression notably in lung cancer models (INSERM unit 981).
Precision
regarding the AGM:
Only shareholders having
registered their shares at least two business days prior to the
date of the AGM, by midnight Paris time, will be able to
attend.
Shareholders holding "au porteur"
(bearer) shares will need to obtain an "attestation de
participation" (certificate of shareholding) from their brokers.
This "attestation de participation" must be attached to the proxy
form or to the appropriate voting form if shareholders wish to
designate a proxy or vote by post. The "attestation de
participation" may replace the admission card for shareholders
wishing to attend the AGM in person.
Written questions from
shareholders must be received from the day of the publication of
the official convocation to the AGM up until four business days
prior to the AGM (by registered letter, addressed to the registered
office, or by e-mail to investors@innate-pharma.com).
Shareholders may obtain the legal
documentation in preparation of the AGM (as described in article R.
225-83 of the French "Code de Commerce") by sending a request:
-
by regular mail to Innate Pharma, Shareholders
Services, 117 avenue de Luminy, BP 30191, F-13009 Marseilles,
France or
-
by e-mail to investors@innate-pharma.com.
About Innate
Pharma:
Innate Pharma S.A. is a
clinical-stage biotechnology company with a focus on discovering
and developing first-in-class therapeutic antibodies that harness
the innate immune system to improve cancer treatment and clinical
outcomes for patients.
Innate Pharma specializes in
immuno-oncology, a new therapeutic field that is changing cancer
treatment by mobilizing the power of the body's immune system to
recognize and kill cancer cells.
The Company's aim is to become a
fully-integrated biopharmaceutical company in the area of
immunotherapy and focused on serious unmet medical needs in cancer.
Innate Pharma has pioneered the discovery and development of
checkpoint inhibitors to activate the innate immune system. Innate
Pharma's innovative approach has resulted in three first-in-class,
clinical-stage antibodies targeting natural killer cell receptors
that may address a broad range of solid and hematological cancer
indications as well as additional preclinical product candidates
and technologies. Targeting receptors involved in innate immunity
also creates opportunities for the Company to develop therapies for
inflammatory diseases.
The Company's expertise and
understanding of natural killer cell biology have enabled it to
enter into major alliances with leaders in the biopharmaceutical
industry including AstraZeneca, Bristol-Myers Squibb and
Sanofi.
Based in Marseille, France, Innate
Pharma has more than 170 employees and is listed on Euronext
Paris.
Learn more about Innate Pharma at
www.innate-pharma.com.
Information about
Innate Pharma shares:
ISIN code
Ticker code |
FR0010331421
IPH |
Disclaimer:
This press release contains
certain forward-looking statements. Although the company believes
its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF,
which is available on the AMF website (http://www.amf-france.org)
or on Innate Pharma's website.
This press release and the
information contained herein do not constitute an offer to sell or
a solicitation of an offer to buy or subscribe to shares in Innate
Pharma in any country.
For additional
information, please contact:
Innate Pharma
Laure-Hélène Mercier
Chief Financial Officer
Tel.: +33 (0)4 30 30 30 87
investors@innate-pharma.com
|
International Media and Investor
Relations
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson
Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com |
ATCG Press (France)
Marie Puvieux
Mob: +33 (0)6 10 54 36 72
presse@atcg-partners.com
|
|
PR in English
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: INNATE PHARMA via Globenewswire
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024